Global Staphylococcal Infection Drugs Markets, 2018-2019 & Forecast to 2023 - ResearchAndMarkets.com

The "Global
Staphylococcal Infection Drugs Market 2019-2023" report has
been added to ResearchAndMarkets.com's offering.

The staphylococcal infection drugs market will register a CAGR of nearly
3% by 2023.

Regulatory agencies are granting special drugs designations for the
development of drugs for the treatment of infectious diseases, including
those used for the treatment of staphylococcal infection. Special drug
designations offer incentives for the development of new drugs for the
treatment which is encouraging more and more manufacturers to invest in
the development of drugs, which in turn is driving the market.

Increasing incidence of staphylococcal infections

The emergence of antibiotics resistant strains has led to increased
incidence of staphylococcal infections. Skin and soft tissue infections
are the most common type of infections caused by staphylococcal. Thus,
rising incidence of staphylococcal infections is a major driver
contributing to the market growth.

Lack of vaccines and new drug classes

Unlike most of the infectious diseases that can be prevented by
vaccines, there is no approved vaccine for the prevention of
staphylococcal infections. The rapid evolution of the bacteria
responsible along with the following factors pose a major hurdle to the
development of vaccines against staphylococcal infections.

Competitive Landscape

The market appears to be fragmented and with the presence of several
companies including Merck & Co. Inc. and Pfizer Inc. the competitive
environment is quite intense. Factors such as the increasing incidence
of staphylococcal infections and special drug designations, will provide
considerable growth opportunities to staphylococcal infection drugs
manufactures.

Allergan Plc, Bayer AG, GlaxoSmithKline Plc, Merck & Co. Inc., and
Pfizer Inc. are some of the major companies covered in this report.

Key Topics Covered:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

• Market ecosystem
• Market characteristics
• Market segmentation analysis

PART 04: MARKET SIZING

• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

• Market segmentation by product
• Comparison by product
• Beta-lactams - Market size and forecast 2018-2023
• Peptides - Market size and forecast 2018-2023
• Quinolones - Market size and forecast 2018-2023
• Macrolides - Market size and forecast 2018-2023
• Others - Market size and forecast 2018-2023
• Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

• Geographic segmentation
• Geographic comparison
• Asia - Market size and forecast 2018-2023
• ROW - Market size and forecast 2018-2023
• North America - Market size and forecast 2018-2023
• Europe - Market size and forecast 2018-2023
• Key leading countries
• Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

• Market drivers
• Market challenges

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

• Overview
• Landscape disruption

PART 13: VENDOR ANALYSIS

• Vendors covered
• Vendor classification
• Market positioning of vendors
• Allergan Plc
• Bayer AG
• GlaxoSmithKline Plc
• Merck & Co. Inc.
• Pfizer Inc.

PART 14: APPENDIX

For more information about this report visit https://www.researchandmarkets.com/r/8132ay

View source version on businesswire.com: https://www.businesswire.com/news/home/20190513005499/en/